Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sonnet BioTherapeutics Holdings ( (SONN) ) has provided an announcement.
Sonnet BioTherapeutics announced promising preclinical data for its lead drug candidate, SON-1010, an albumin-binding IL-12 fusion protein, aimed at improving cancer treatment efficacy. By enhancing cytokine half-life and tumor targeting, SON-1010 shows potential in combating solid tumors, including ovarian cancer, with ongoing Phase 1/2a clinical trials in collaboration with Roche. This breakthrough could revolutionize cancer immunotherapy, offering a new hope for treatment-resistant cancers.
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Can MicroStrategy Stock Reach Around $1,000? Here’s What This Investor Expects
- Bank of America Chimes in on Intel Stock, Warning of a Bumpy Road Ahead
- ‘Don’t Jump on the Bandwagon,’ Says J.P. Morgan About Super Micro Computer Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
